ACRS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.6M
-18.4%
2.0M
+54.1%
1.3M
-60.7%
3.3M
+85.6%
1.8M
Cost of Revenue
218.0K
-44.8%
395.0K
-25.8%
532.0K
-1.1%
538.0K
+4.5%
515.0K
Gross Profit
1.4M
-11.9%
1.6M
+109.8%
763.0K
-72.4%
2.8M
+118.8%
1.3M
Operating Expenses
25.6M
+7.8%
23.8M
+1.3%
23.5M
+18.0%
19.9M
+1.2%
19.7M
R&D
18.1M
+15.4%
15.7M
-5.6%
16.6M
+27.3%
13.0M
+13.8%
11.4M
SG&A
6.0M
-10.3%
6.7M
+20.9%
5.6M
+14.5%
4.9M
-9.6%
5.4M
Operating Income
-24238000
-9.2%
-22192000
+2.4%
-22734000
-32.6%
-17149000
+6.8%
-18408000
EBITDA
-24131000
-9.2%
-22090000
+0.6%
-22232000
-31.2%
-16939000
+7.4%
-18294000
Net Income
-21505000
-8.5%
-19824000
-0.1%
-19795000
-35.5%
-14614000
+5.3%
-15429000
EPS (Basic)
$-0.15
+0.0%
$-0.15
+6.3%
$-0.16
-33.3%
$-0.12
+7.7%
$-0.13
EPS (Diluted)
$-0.15
+0.0%
$-0.15
+6.3%
$-0.16
-33.3%
$-0.12
+7.7%
$-0.13
Shares (Diluted)
142.7M
+10.8%
128.8M
+5.0%
122.7M
+0.0%
122.6M
+0.0%
122.6M
Aclaris Therapeutics (ACRS) โ€” Financials